Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Chubb
UBS
Johnson and Johnson
Fuji
Merck

Generated: July 23, 2019

DrugPatentWatch Database Preview

Patent: 9,957,541

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,957,541
Title:Cell expression system
Abstract: An expression system for expressing a protein comprising: a eukaryotic host cell carrying a dihydrofolate reductase (DHFR) deficiency; and an expression vector, the expression vector encoding the human growth hormone gene; a expression vector, the expression vector comprising: a eukaryotic selectable marker including a minimal SV 40 early promoter driving expression of a sequence encoding dihydrofolate reductase for complementing the DHFR deficiency in the host cell; a prokaryotic selectable marker conveying Ampicillin resistance to a prokaryotic host cell; a prokaryotic Origin of Replication; a plurality of multiple cloning sites (MCS); and at least one protein expression module comprising: a Simian Vacuolating Virus 40 (SV40) early promoter, inclusive of its 72 bp enhancer repeats; and a rabbit .beta.-globin intron sequence being separable from a SV40 p A sequence by a first multiple cloning site, for receiving a coding sequence and expressing a desired protein therefrom.
Inventor(s): Sunstrom; Noelle (Eveleigh, AU)
Assignee: NeuClone Biologics Pty Ltd (Eveleigh, NSW, AU)
Application Number:15/148,930
Patent Claims:see list of patent claims

Details for Patent 9,957,541

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30 ➤ Sign Up NeuClone Biologics Pty Ltd (Eveleigh, NSW, AU) ➤ Sign Up RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up NeuClone Biologics Pty Ltd (Eveleigh, NSW, AU) ➤ Sign Up RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up NeuClone Biologics Pty Ltd (Eveleigh, NSW, AU) ➤ Sign Up RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ➤ Sign Up NeuClone Biologics Pty Ltd (Eveleigh, NSW, AU) ➤ Sign Up RX Orphan search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31 ➤ Sign Up NeuClone Biologics Pty Ltd (Eveleigh, NSW, AU) ➤ Sign Up RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Sign Up NeuClone Biologics Pty Ltd (Eveleigh, NSW, AU) ➤ Sign Up RX search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02 ➤ Sign Up NeuClone Biologics Pty Ltd (Eveleigh, NSW, AU) ➤ Sign Up RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 9,957,541

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2014134657 Sep 12, 2014
United States of America 2016017281 Jan 21, 2016
United States of America 2016244799 Aug 25, 2016
United States of America 2018100176 Apr 12, 2018
United States of America 2018195102 Jul 12, 2018
United States of America 9404078 Aug 02, 2016
Singapore 11201506926S Sep 29, 2015
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Merck
Teva
Baxter
Colorcon
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.